报价延迟最少15分钟:2025/07/21 16:22 EDT
盘后时段
|
||||
|
0.7932 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.803
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-7.69/-1.77
|
|
企业价值
5.44M
|
| 资产负债 |
|
每股账面净值
1.83
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 16:22 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers. |
